Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer

Nenhuma Miniatura disponível
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
MASSACHUSETTS MEDICAL SOC
Autores
HADOUX, J.
ELISEI, R.
BROSE, M. S.
ROBINSON, B. G.
GAO, M.
JARZAB, B.
ISAEV, P.
KOPECKOVA, K.
WADSLEY, J.
Citação
NEW ENGLAND JOURNAL OF MEDICINE, v.389, n.20, p.1851-1861, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear.Methods We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end point in the protocol-specified interim efficacy analysis was progression-free survival, assessed by blinded independent central review. Crossover to selpercatinib was permitted among patients in the control group after disease progression. Treatment failure-free survival, assessed by blinded independent central review, was a secondary, alpha-controlled end point that was to be tested only if progression-free survival was significant. Among the other secondary end points were overall response and safety.Results A total of 291 patients underwent randomization. At a median follow-up of 12 months, median progression-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 16.8 months (95% confidence interval [CI], 12.2 to 25.1) in the control group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.16 to 0.48; P<0.001). Progression-free survival at 12 months was 86.8% (95% CI, 79.8 to 91.6) in the selpercatinib group and 65.7% (95% CI, 51.9 to 76.4) in the control group. Median treatment failure-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 13.9 months in the control group (hazard ratio for disease progression, discontinuation due to treatment-related adverse events, or death, 0.25; 95% CI, 0.15 to 0.42; P<0.001). Treatment failure-free survival at 12 months was 86.2% (95% CI, 79.1 to 91.0) in the selpercatinib group and 62.1% (95% CI, 48.9 to 72.8) in the control group. The overall response was 69.4% (95% CI, 62.4 to 75.8) in the selpercatinib group and 38.8% (95% CI, 29.1 to 49.2) in the control group. Adverse events led to a dose reduction in 38.9% of the patients in the selpercatinib group, as compared with 77.3% in the control group, and to treatment discontinuation in 4.7% and 26.8%, respectively.Conclusions Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.)
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/59124
Referências
  1. [Anonymous], 2017, Common Terminology Criteria for Adverse Events
  2. Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137
  3. Brose MS, 2018, CANCER TREAT REV, V66, P64, DOI 10.1016/j.ctrv.2018.04.007
  4. Carlomagno F, 2004, ONCOGENE, V23, P6056, DOI 10.1038/sj.onc.1207810
  5. Cerrato A, 2009, J MOL ENDOCRINOL, V43, P143, DOI 10.1677/JME-09-0024
  6. Ciampi R, 2019, ISCIENCE, V20, P324, DOI 10.1016/j.isci.2019.09.030
  7. Drìlon A, 2020, NEW ENGL J MED, V383, P813, DOI 10.1056/NEJMoa2005653
  8. Drilon A, 2023, J CLIN ONCOL, V41, P385, DOI 10.1200/JCO.22.00393
  9. Drosten M, 2006, NAT CLIN PRACT ONCOL, V3, P564, DOI 10.1038/ncponc0610
  10. Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
  11. Elisei R, 2008, J CLIN ENDOCR METAB, V93, P682, DOI 10.1210/jc.2007-1714
  12. Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
  13. Filetti S, 2022, ANN ONCOL, V33, P674, DOI 10.1016/j.annonc.2022.04.009
  14. Filetti S, 2019, ANN ONCOL, V30, P1856, DOI 10.1093/annonc/mdz400
  15. Vuong HG, 2018, ENDOCR-RELAT CANCER, V25, P633, DOI 10.1530/ERC-18-0056
  16. Kouvaraki MA, 2005, THYROID, V15, P531, DOI 10.1089/thy.2005.15.531
  17. Kreissl MC, 2020, J CLIN ONCOL, V38, P2773, DOI 10.1200/JCO.19.02790
  18. LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.1093/biomet/80.3.557
  19. MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0
  20. Romei Cristina, 2018, Oncotarget, V9, P9875, DOI 10.18632/oncotarget.23986
  21. Romei C, 2016, J MED GENET, V53, P729, DOI 10.1136/jmedgenet-2016-103833
  22. Subbiah V, 2018, ANN ONCOL, V29, P1869, DOI 10.1093/annonc/mdy137
  23. TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1
  24. United States Securities and Exchange Commission, 2023, FORM 8 K
  25. Wang LH, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032312
  26. Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
  27. Wirth LJ, 2020, NEW ENGL J MED, V383, P825, DOI 10.1056/NEJMoa2005651
  28. Wirth LJ, 2022, FUTURE ONCOL, V18, P3143, DOI 10.2217/fon-2022-0657
  29. Wirth LJ, 2022, ONCOLOGIST, V27, P13, DOI 10.1002/onco.13977
  30. Zheng XQ, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221119318

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP